JP4095805B2 - ユビキチンリガーゼアッセイ - Google Patents

ユビキチンリガーゼアッセイ Download PDF

Info

Publication number
JP4095805B2
JP4095805B2 JP2001573019A JP2001573019A JP4095805B2 JP 4095805 B2 JP4095805 B2 JP 4095805B2 JP 2001573019 A JP2001573019 A JP 2001573019A JP 2001573019 A JP2001573019 A JP 2001573019A JP 4095805 B2 JP4095805 B2 JP 4095805B2
Authority
JP
Japan
Prior art keywords
tag
ubiquitin
group
curin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001573019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529372A (ja
Inventor
サーキズ・ディ・イサカニ
ジャニン・フアン
ジュリー・シュン
トッド・アール・プレイ
Original Assignee
ライジェル・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル・ファーマシューティカルズ・インコーポレイテッド filed Critical ライジェル・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2003529372A publication Critical patent/JP2003529372A/ja
Application granted granted Critical
Publication of JP4095805B2 publication Critical patent/JP4095805B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001573019A 2000-04-03 2001-04-03 ユビキチンリガーゼアッセイ Expired - Fee Related JP4095805B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/542,497 US6740495B1 (en) 2000-04-03 2000-04-03 Ubiquitin ligase assay
US09/542,497 2000-04-03
PCT/US2001/010906 WO2001075145A2 (en) 2000-04-03 2001-04-03 Ubiquitin ligase assay

Publications (2)

Publication Number Publication Date
JP2003529372A JP2003529372A (ja) 2003-10-07
JP4095805B2 true JP4095805B2 (ja) 2008-06-04

Family

ID=24164065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001573019A Expired - Fee Related JP4095805B2 (ja) 2000-04-03 2001-04-03 ユビキチンリガーゼアッセイ

Country Status (9)

Country Link
US (5) US6740495B1 (de)
EP (1) EP1268847B1 (de)
JP (1) JP4095805B2 (de)
AT (1) ATE377654T1 (de)
AU (1) AU2001251291A1 (de)
DE (1) DE60131262T2 (de)
DK (1) DK1268847T3 (de)
ES (1) ES2296744T3 (de)
WO (1) WO2001075145A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378248B2 (en) * 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
US6979551B2 (en) * 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US20020028472A1 (en) * 2000-06-29 2002-03-07 Michael Gmachl Methods for identifying inhibitors of the anaphase promoting complex
DE10108263A1 (de) * 2001-02-21 2002-09-05 Max Planck Gesellschaft Analyse von Modifizierungen und Demodifizierungen von Proteinen mit Ubiquitinverwandten Proteinen mittels FRET (Fluorescence Resonance Energy Transfer)
WO2003023405A1 (en) 2001-09-07 2003-03-20 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of f-box proteins for alzheimer's disease and related neurodegenerative disorders
AU2002352797A1 (en) * 2001-11-19 2003-06-10 Proteologics, Inc. Methods for identifying and validating potential drug targets
US7736846B2 (en) * 2002-08-30 2010-06-15 Rigel Pharmaceuticals, Inc. Methods of assaying for modulators of the inflammatory process using components of the ubiquitin ligation cascade
US7723018B2 (en) 2002-08-30 2010-05-25 Rigel Pharmaceuticals, Incorporated Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
EP1867731A3 (de) 2002-08-30 2008-03-12 Rigel Pharmaceuticals, Inc. Verfahren zum Testen von Modulatoren von Entzündungsprozessen über Teile der Ubiquitinbindungskaskade
US7052843B2 (en) 2002-10-08 2006-05-30 New York University Transcription-based assay for identification of post-translational modification and its application in proteomics
US7312197B2 (en) * 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US20070122807A1 (en) * 2003-04-03 2007-05-31 Proteologics, Inc. Posh polypeptides, complexes and related methods
WO2005000876A2 (en) * 2003-06-27 2005-01-06 Proteologics, Inc. Ring finger family proteins and uses related thereto
US7132234B2 (en) * 2003-10-28 2006-11-07 Rigel Pharmaceuticals, Inc. Methods and compositions for the identification of anti-poxvirus agents
WO2005047476A2 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation
EP1595945A1 (de) * 2004-05-14 2005-11-16 Boehringer Ingelheim International GmbH Screeningverfahren zur Identifizierung von Verbindungen, die die Wirkung von Myc inhibieren können.
JP2008517278A (ja) * 2004-10-15 2008-05-22 シグナル ファーマシューティカルズ，エルエルシー ｐ２７のユビキチン化アッセイ及びその使用方法
US20090263821A1 (en) * 2004-12-01 2009-10-22 Proteologics, Inc. Ubiquitin Ligase Assays And Related Reagents
US9051572B2 (en) 2005-01-20 2015-06-09 Ryboquin Company Limited Modulators of Itch ubiquitinase activity
US20060246543A1 (en) * 2005-03-03 2006-11-02 President And Fellows Of Harvard College Slim compositions and methods of use thereof
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
EP1891434B1 (de) * 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
KR100877824B1 (ko) * 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
US9066976B2 (en) 2005-11-11 2015-06-30 Korea Research Institute Of Bioscience And Biotechnology Method for therapeutic angiogenesis
US8058014B2 (en) * 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
KR20090090383A (ko) 2006-12-14 2009-08-25 다이이찌 산쿄 가부시키가이샤 이미다조티아졸 유도체
US20100099096A1 (en) * 2007-02-28 2010-04-22 The Brigham And Women's Hospital, Inc. Compositions and Methods for Identifying Factors Affecting Protein Stability
US7892772B2 (en) * 2007-03-12 2011-02-22 Iti Scotland Limited Targeted ubiquitination of proteins and screening methods using a new class of ubiquitin ligase proteins
MX344555B (es) 2007-05-08 2016-12-20 Hunter Douglas Ind Switzerland Sistema de color multivariado con aplicacion de textura.
AR069824A1 (es) 2007-09-14 2010-02-24 Basf Plant Science Gmbh Plantas con rasgos aumentados relacionados con el rendimiento y un metodo para producirlas
FR2924721B1 (fr) * 2007-12-10 2010-02-26 Cytomics Systems Procede de criblage d'agents modulant l'activite de l'ubiquitine ligase mdm2 et moyens destines a la mise en oeuvre dudit procede
WO2009134897A1 (en) * 2008-04-29 2009-11-05 Burnham Institute For Medical Research E3-independent ubiquitinylation assay
US8513181B2 (en) * 2008-04-29 2013-08-20 Cornell University Substances and compositions for enhancing DNA repair and methods of use
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
US20100021941A1 (en) * 2008-07-25 2010-01-28 Progenra, Incorporated Methods of identifying modulators of ubiquitin ligases
WO2010042828A2 (en) * 2008-10-09 2010-04-15 The Penn State Research Foundation Methods and compositions relating to e3 ring-e2 fusion proteins
PT2380892E (pt) 2009-01-16 2014-06-09 Daiichi Sankyo Co Ltd Derivado de imidazotiazole compreendendo uma estrutura de anel prolina
US20130131153A1 (en) * 2009-11-16 2013-05-23 The Johns Hopkins University Cullin 5 as a regulator of hsp90 clients: a new target for drug development
BR112012017165A2 (pt) 2010-01-12 2015-09-15 Ahram Biosystems Inc aparelho de convecção térmica de três estágios e usos do mesmo.
GB201006604D0 (en) 2010-04-20 2010-06-02 Iti Scotland Ltd Ubiquitination assay
GB201007185D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination assay
WO2011151826A2 (en) * 2010-06-01 2011-12-08 Ben-Gurion University Of The Negev Research And Development Authority An expeditious synthesis of ubiquitinated peptide conjugates
US9383367B1 (en) 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
WO2013042120A2 (en) 2011-09-19 2013-03-28 Proteologics Ltd Synthetic ubiquitins and use thereof in drug screening assays
CA2861066C (en) * 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
EP2805281A4 (de) * 2012-01-18 2015-09-09 Singular Bio Inc Verfahren zur abbildung von strichcodierten molekülen zur erkennung von strukturvariationen und sequenzierungen
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016138574A1 (en) 2015-03-02 2016-09-09 Sinai Health System Homologous recombination factors
WO2017044793A1 (en) 2015-09-11 2017-03-16 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of cereblon
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
US11604186B2 (en) * 2018-10-17 2023-03-14 Molecular Devices (Austria) GmbH Real time western blot assays utilizing fluorescence resonance energy transfer (FRET)
CN111208243B (zh) * 2018-11-21 2022-05-17 中国科学院大连化学物理研究所 一种基于阴离子交换色谱柱的sumo化肽段的富集方法
WO2022187342A1 (en) * 2021-03-02 2022-09-09 The Board Of Regents Of The University Of Texas System Methods and compositions for detecting protein targets
WO2023096721A1 (en) * 2021-11-23 2023-06-01 Board Of Regents, The University Of Texas System Fret-active e2-ubl conjugates and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5384255A (en) * 1993-06-21 1995-01-24 Rappaport Family Institute For Research In The Medical Sciences Ubiquitin carrier enzyme E2-F1, purification, production, and use
DE69517010T2 (de) * 1994-01-04 2000-12-21 Mitotix Inc Ubiquitin-konjugierende enzyme
US5744343A (en) * 1994-01-04 1998-04-28 Mitotix, Inc. Ubiquitin conjugating enzymes
WO1995027066A2 (en) * 1994-03-31 1995-10-12 Univ Leeds Dna encoding ubiquitin conjugating enzymes
US6127158A (en) * 1994-12-07 2000-10-03 President And Fellows Of Harvard College Ubiquitin conjugating enzymes
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US6001619A (en) * 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US5861249A (en) * 1996-04-23 1999-01-19 Cold Spring Harbor Laboratory Assays and reagents for identifying modulators of cdc25-mediated mitotic activation
US5840866A (en) * 1996-07-10 1998-11-24 Incyte Pharmaceuticals, Inc. Human ubiquitin-conjugating enzyme
EP0843008A1 (de) 1996-11-14 1998-05-20 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von dem Anaphase-fördernden Komplex
US5817494A (en) * 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
US6060262A (en) * 1997-07-16 2000-05-09 Mitotix, Inc. Regulation of I Kappa B (IκB) degradation and methods and reagents related thereto
AU8555798A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
EP1000151B1 (de) 1997-08-01 2006-05-31 Serono Genetics Institute S.A. 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
AU9664598A (en) * 1997-09-23 1999-04-12 Incyte Pharmaceuticals, Inc. Human ubiquitin-conjugating enzymes
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
US6426205B1 (en) * 1997-10-24 2002-07-30 Mount Sinai Hospital Corporation Methods and compositions for modulating ubiquitin dependent proteolysis
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
WO1999032514A2 (en) 1997-12-19 1999-07-01 Warner-Lambert Company Sag: sensitive to apoptosis gene
GB9727277D0 (en) 1997-12-23 1998-02-25 Medical Res Council Assay
US6165731A (en) * 1998-01-22 2000-12-26 California Institute Of Technology Assay for the ubiquitination-promoting activity of human proteins
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
US6413725B1 (en) * 1998-08-07 2002-07-02 California Institute Of Technology Biochemical assay to monitor the ubiquitin ligase activities of cullins
AU2342900A (en) * 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
WO2000022110A2 (en) 1998-10-09 2000-04-20 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
US6306663B1 (en) * 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
WO2000050631A2 (en) 1999-02-25 2000-08-31 Cyclacel Limited Compositions and methods for monitoring the modification of natural binding partners
CA2362520A1 (en) 1999-02-26 2000-08-31 Joan W. Conaway Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1165787A2 (de) 1999-03-31 2002-01-02 The University of North Carolina at Chapel Hill Cullin regulatoren roc1 und roc2, dafür kodierende dna, und methoden zur ihrer verwendug
JP2001192152A (ja) * 2000-01-11 2001-07-17 Fuji Photo Film Co Ltd 給紙マガジン
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
WO2001097830A1 (en) 2000-06-22 2001-12-27 Mount Sinai School Of Medicine Modification of mdm2 activity
EP1167539A1 (de) 2000-06-29 2002-01-02 Boehringer Ingelheim International GmbH Verfahren zur Identifizierung von Verbindungen die das Anaphae-fördernde Komplex hemmen
US6526205B1 (en) * 2000-10-13 2003-02-25 Agilent Technologies, Inc. Method and apparatus for the passive alignment of optical components
DE10108263A1 (de) 2001-02-21 2002-09-05 Max Planck Gesellschaft Analyse von Modifizierungen und Demodifizierungen von Proteinen mit Ubiquitinverwandten Proteinen mittels FRET (Fluorescence Resonance Energy Transfer)

Also Published As

Publication number Publication date
AU2001251291A1 (en) 2001-10-15
DE60131262T2 (de) 2008-08-28
DE60131262D1 (en) 2007-12-20
US20060105409A1 (en) 2006-05-18
JP2003529372A (ja) 2003-10-07
US7781182B2 (en) 2010-08-24
US20020042083A1 (en) 2002-04-11
DK1268847T3 (da) 2008-03-10
US6740495B1 (en) 2004-05-25
EP1268847B1 (de) 2007-11-07
US7022493B2 (en) 2006-04-04
WO2001075145A3 (en) 2002-07-25
EP1268847A2 (de) 2003-01-02
US20050032139A1 (en) 2005-02-10
US6737244B2 (en) 2004-05-18
ATE377654T1 (de) 2007-11-15
US20090263831A1 (en) 2009-10-22
ES2296744T3 (es) 2008-05-01
WO2001075145A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
JP4095805B2 (ja) ユビキチンリガーゼアッセイ
US7524642B2 (en) Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
Mullen et al. Activation of the Slx5–Slx8 ubiquitin ligase by poly-small ubiquitin-like modifier conjugates
EP1417493B1 (de) Kompetitiver bindungstest zur identifikation von hcv-polymeraseinhibitoren
EP1540015A2 (de) Assays und zusammensetzungen zur identifizierung von die aktivität deubiquitinierender agentien modulierenden agentien
EP1392870B1 (de) Screening auf enzyminhibitoren
EP1163363B1 (de) Verfahren und zusammensetzungen zur überwachung der modifikation von natürlichen bindungspartners
US20060088901A1 (en) Methods and kits for determining ubiquitin protein ligase (E3) activity
US6919184B2 (en) Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
WO2002066982A2 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
US20070026431A1 (en) Modulation of MAPK-mediated phosphorylation and/or FBXW8-mediated ubiquitinylation of cyclin D1 in modulation of cellular proliferation
US6284461B1 (en) Use of inhibitors in reporter assays
JP2007513878A (ja) 宿主細胞のユビキチン化の調節を通じたレトロウイルス複製の阻害
US20040241782A1 (en) Methods and means for detecting enzymatic cleavage and linkage reactions
WO2003102172A1 (en) Methods and compositions for a ubiquitin map
KR20050042264A (ko) 스테로이드생성 조절 및 조작을 위한 방법 및 조성물
US20030104496A1 (en) Novel motor protein of P. falciparum and methods for its use

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20041124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080310

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110314

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4095805

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110314

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120314

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130314

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140314

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees